Biosimilar concerns of rheumatology patients being addressed by national program

(European League Against Rheumatism) To address the fear and insecurity expressed by rheumatology patients on being switched from a biologic to a biosimilar treatment for their arthritis, the Danish Rheumatism Association has participated in a national program designed to ensure patients received independent information about biosimilars, along with closer monitoring of prescriptions to provide reassurance about their safety. The results of this initiative were presented today at the Annual European Congress of Rheumatology 2017.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news